{"disease":{"id":"hiv-disease","name":"hiv disease"},"drugs":{"marketed":[{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and HIV infection and sickle cell disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":19,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT01681420","title":"Improving Blood Safety and HIV Testing in Brazil","phase":"NA","overall_status":"COMPLETED","enrollment_count":11900,"lead_sponsor_name":"Vitalant Research Institute","has_results":false},{"nct_id":"NCT06492187","title":"Triage Survey for Infectious Disease Eligibility","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brooklyn Clinical Research","has_results":false},{"nct_id":"NCT05580666","title":"Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"Population Health Research Institute","has_results":false},{"nct_id":"NCT02344290","title":"Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":7769,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT04349748","title":"MHealth Intervention of HIV and STDs Partner Notification for MSM","phase":"NA","overall_status":"UNKNOWN","enrollment_count":6172,"lead_sponsor_name":"National Institute on Drug Dependence, China","has_results":false},{"nct_id":"NCT05405582","title":"Thetha Nami Ngithethe Nawe (\"Let's Talk\"): Step Wedge cRCT of Peer Led Community PrEP and SRH for Youth in South Africa","phase":"NA","overall_status":"UNKNOWN","enrollment_count":6000,"lead_sponsor_name":"Africa Health Research Institute","has_results":false},{"nct_id":"NCT05516069","title":"Our Healthbox - Evaluating Interactive Dispensing Systems for Low-Barrier Access to HIV Testing and Harm Reduction.","phase":"NA","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Unity Health Toronto","has_results":false},{"nct_id":"NCT05685810","title":"Genetic Determinants of Kidney Disease in People of African Ancestry With HIV","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3029,"lead_sponsor_name":"King's College Hospital NHS Trust","has_results":false},{"nct_id":"NCT04446156","title":"Liver Diseases in PLWH","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT00001281","title":"Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV","phase":"","overall_status":"RECRUITING","enrollment_count":2419,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT05085171","title":"An Enhanced Package of Care to Reduce Reduce Mortality in Advanced HIV Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":2400,"lead_sponsor_name":"Makerere University","has_results":false},{"nct_id":"NCT05655546","title":"ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals","phase":"NA","overall_status":"TERMINATED","enrollment_count":2117,"lead_sponsor_name":"Scripps Translational Science Institute","has_results":true},{"nct_id":"NCT04025125","title":"Pathways to Cardiovascular Disease Prevention (DCRI Central and Statistical Coordinating Center)","phase":"","overall_status":"COMPLETED","enrollment_count":2039,"lead_sponsor_name":"Duke University","has_results":true},{"nct_id":"NCT04060420","title":"Yathu Yathu: An Impact Evaluation of Community-based Peer-led Sexual and Reproductive Health Services","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":false},{"nct_id":"NCT05473325","title":"Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Willows Health","has_results":false},{"nct_id":"NCT04330287","title":"HIV-HEART Aging Study","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University Hospital, Essen","has_results":false},{"nct_id":"NCT04156048","title":"HIV&HEART Aging Study (12,5 Year Follow up)","phase":"","overall_status":"COMPLETED","enrollment_count":1809,"lead_sponsor_name":"University Hospital, Essen","has_results":false},{"nct_id":"NCT04033120","title":"Making an Early Diagnosis of Talaromycosis Using a Novel Antigen Test","phase":"","overall_status":"COMPLETED","enrollment_count":1411,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT07072481","title":"Sustaining Innovative Tools to Expand Youth-Friendly HIV Self-Testing","phase":"NA","overall_status":"RECRUITING","enrollment_count":1216,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT06503666","title":"Zambian Informed Motivated Aware Responsible Adolescent Girls and Adults","phase":"NA","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Centre for Infectious Disease Research in Zambia","has_results":false},{"nct_id":"NCT04417127","title":"Harambee: Integrated Community-based HIV/NCD Care & Microfinance Groups in Kenya","phase":"NA","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"Brown University","has_results":true},{"nct_id":"NCT05983536","title":"The Evaluation of Anti-interference Ability and Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)","phase":"","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"Qianfoshan Hospital","has_results":false},{"nct_id":"NCT04568967","title":"TB-CAPT EXULTANT - HIV","phase":"NA","overall_status":"COMPLETED","enrollment_count":1172,"lead_sponsor_name":"Foundation for Innovative New Diagnostics, Switzerland","has_results":false},{"nct_id":"NCT02382822","title":"Copenhagen Comorbidity in HIV Infection Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1099,"lead_sponsor_name":"Susanne Dam Nielsen, MD, DMSc","has_results":false},{"nct_id":"NCT00006518","title":"Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1029,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05541081","title":"Investigating Point-of-care Diagnostics for Sexually Transmitted Infections and Antimicrobial Resistance in Primary Care in Zimbabwe","phase":"NA","overall_status":"COMPLETED","enrollment_count":1005,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":false},{"nct_id":"NCT05868005","title":"Delivering a Multi-disease Screening Tool to Migrant Populations","phase":"NA","overall_status":"COMPLETED","enrollment_count":980,"lead_sponsor_name":"Barcelona Institute for Global Health","has_results":false},{"nct_id":"NCT04772469","title":"Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men","phase":"NA","overall_status":"COMPLETED","enrollment_count":934,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT03996941","title":"Harm Reduction Program For Informal PrEP Users In A Community-based Setting (seguiPrEP)","phase":"","overall_status":"UNKNOWN","enrollment_count":900,"lead_sponsor_name":"BCN Checkpoint","has_results":false},{"nct_id":"NCT03129308","title":"Prevalence of Cutaneous Autoimmune Phenomena in HIV Infected Patients","phase":"","overall_status":"COMPLETED","enrollment_count":842,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT05463692","title":"CAMELLIA Cohort: A Longitudinal Study to Understand Sexual Health and Prevention Among Women in Alabama","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":830,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT05708014","title":"Personalized Prevention for Couples: A 16-month Digital RCT","phase":"NA","overall_status":"COMPLETED","enrollment_count":778,"lead_sponsor_name":"Florida International University","has_results":false},{"nct_id":"NCT05657106","title":"Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":752,"lead_sponsor_name":"April M Young","has_results":false},{"nct_id":"NCT03678181","title":"Increasing Engagement and Improving HIV Outcomes Via HealthMPowerment","phase":"NA","overall_status":"COMPLETED","enrollment_count":750,"lead_sponsor_name":"University of Pennsylvania","has_results":true},{"nct_id":"NCT02178930","title":"HealthMap: an Interactive Health Plan Randomised Trial to Prevent Cardiovascular Disease in People With HIV","phase":"NA","overall_status":"COMPLETED","enrollment_count":731,"lead_sponsor_name":"Karen Klassen","has_results":false},{"nct_id":"NCT05998499","title":"HIV-Infected Latin American Asylum Seekers in Europe: Insights From the EuroLatin HIV Cohort","phase":"","overall_status":"COMPLETED","enrollment_count":631,"lead_sponsor_name":"Hospital Universitario Infanta Leonor","has_results":false},{"nct_id":"NCT01208792","title":"Auto-immunity and Pulmonary Arterial Hypertension","phase":"NA","overall_status":"COMPLETED","enrollment_count":629,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03155841","title":"Reducing HIV Vulnerability Through A Multilevel Life Skills Intervention For Adolescent Men","phase":"NA","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"University of Pennsylvania","has_results":true},{"nct_id":"NCT06072287","title":"The Living With a Long-Term Condition Study","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"King's College London","has_results":false},{"nct_id":"NCT03436407","title":"Evaluation of Implementation of Pre-exposure Prophylaxis (PrEP) in Norway","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT04313699","title":"Geriatric HIV Cohort in Sub Sahara Africa","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Makerere University","has_results":false},{"nct_id":"NCT05688709","title":"Acceptability, Feasibility and Effectiveness of Online Peer Support Group for ART Adherence Among Youth","phase":"NA","overall_status":"UNKNOWN","enrollment_count":488,"lead_sponsor_name":"Infectious Diseases Research Collaboration, Uganda","has_results":false},{"nct_id":"NCT05525156","title":"The Effect of Aspirin on HIV Disease Progression Among HIV- Infected Individuals Initiating Anti- Retroviral Therapy","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":454,"lead_sponsor_name":"Muhimbili University of Health and Allied Sciences","has_results":false},{"nct_id":"NCT04851015","title":"Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":416,"lead_sponsor_name":"Todd C. Lee MD MPH FIDSA","has_results":false},{"nct_id":"NCT03512210","title":"Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","has_results":true},{"nct_id":"NCT04070287","title":"Innovative Tools to Expand HIV Self-Testing","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":388,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT03965221","title":"Comparison of Men's Prevention Apps to Research Efficacy","phase":"NA","overall_status":"COMPLETED","enrollment_count":381,"lead_sponsor_name":"Public Health Foundation Enterprises, Inc.","has_results":false},{"nct_id":"NCT03810170","title":"Prevention of HIV/AIDS and STDs in Women Over Fifty","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":331,"lead_sponsor_name":"Environment and Health Group, Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}